Novo Nordisk comments on role of off-label use in Ozempic shortfall
Novo Nordisk promotes new GLP-1 receptor agonist to fight diabetes, obesity < Pharma < Article - KBR
New GLP-1 weight loss drugs are about to ship to more American homes
Another Weight-Loss Trial Win for Weekly GLP-1 Drug | MedPage Today
Novo Nordisk 2018: Struggling against the tide – PharmaLive
Novo's fast-launching Ozempic puts Lilly on notice—and its GLP-1 pill is on its way | Fierce Pharma
Long-acting GLP-1 analogue #1
Novo Nordisk Stock: Growing Obesity Epidemic Will Generate Demand (NYSE:NVO) | Seeking Alpha
Novo Nordisk looks to HEOR data to back Victoza | Pharmafile
Novo Nordisk doesn't feel threatened by GLP-1 rival Lilly
A pharmaceutical jack of all trades? Novo CEO touts semaglutide's potential in NASH, Alzheimer's and its hot start in obesity | Fierce Pharma
Frontiers | Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
The 411 on a GLP-1
GLP-1 diabetes drugs are being released one after another
Novo Nordisk's Rybelsus (semaglutide) is a first oral GLP-1 treatment for type 2 diabetes mellitus - YouTube
The 411 on a GLP-1“ auf Apple Podcasts
Novo Nordisk grows GLP-1 market share in Q2 in the US with Ozempic® and Rybelsus® - MidgardFinance.com
FDA Approves Novo Nordisk's Saxenda as a Treatment for Chronic Weight Management
GLP-1: The Reliable Partner | circulatory system | GLP-1 is your reliable partner in treating type 2 diabetes. They work by mimicking the functions of natural incretin hormones -- including stimulating... | By Novo Nordisk | Facebook
Novo Nordisk: Switch To Weekly Ozempic Has Begun, Biopharma M&A Sought :: Scrip
